anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Tonsillectomy or adenotonsillectomy versus non‐surgical treatment for chronic/recurrent acute tonsillitis
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Chronic Tonsillitis 7. Recurrent Acute Tonsillitis 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Amplification with hearing aids for patients with tinnitus and co‐existing hearing loss
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Hearing impairment 5. Young Adult 19-24 years 6. Tinnitus 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Birth to 1 mo 5. Acute Otitis Media
Provide patient population that should be included in the study
Nebulized epinephrine for croup in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Infant 1 to 23 mo 4. Croup 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral rinses, mouthwashes and sprays for improving recovery following tonsillectomy
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Tonsillectomy 6. Young Adult 19-24 years 7. Tonsillectomy & Adenoidectomy 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Steroids for idiopathic sudden sensorineural hearing loss
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Sudden Sensorineural Hearing Loss 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Acetaminophen (paracetamol) for the common cold in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Common Cold 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Intranasal ipratropium bromide for the common cold
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Child 6-12 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Common Cold 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Antibiotics for the common cold and acute purulent rhinitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Purulent Rhinitis 9. Birth to 1 mo 10. Common Cold 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho‐pulmonary disease
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Acute Lower Respiratory Tract Infection 4. Acute Upper Respiratory Infection 5. Infant 1 to 23 mo 6. Birth to 1 mo 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Autoinflation for hearing loss associated with otitis media with effusion
1. Child, Preschool 2-5 years 2. Adult 19-44 years 3. Child 6-12 years 4. Otitis Media with Effusion 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for the prevention of postoperative ear discharge after insertion of ventilation tubes (grommets) in children
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Otitis Media with Effusion 4. Infant 1 to 23 mo 5. Ventilation Tube In Tympanic Membrane 6. Adolescent 13-18 years 7. Recurrent Acute Otitis Media
Provide patient population that should be included in the study
Surgery for Ménière's disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Meniere's Disease 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Clinical service organisation for adults with atrial fibrillation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Atrial Fibrillation 6. Aged 65-79 years
Provide patient population that should be included in the study
Collaborative care approaches for people with severe mental illness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Schizophreniform Disorder 5. Young Adult 19-24 years 6. Schizophrenia 7. Schizophrenic Psychoses 8. Aged 65-79 years 9. Schizoaffective Schizophrenia
Provide patient population that should be included in the study
Admission avoidance hospital at home
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Primary‐level and community worker interventions for the prevention of mental disorders and the promotion of well‐being in low‐ and middle‐income countries
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions to improve the appropriate use of polypharmacy for older people
1. Aged 80 and over 80+ years 2. Chronic Disease 3. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for the uptake of evidence‐based recommendations in acute stroke settings
1. Hemorrhagic stroke 2. Ischemic Stroke
Provide patient population that should be included in the study
Acute assessment services for patient flow assistance in hospital emergency departments
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Hospital admission 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Pharmacological, non‐invasive brain stimulation and psychological interventions, and their combination, for treating depression after stroke
1. Stroke 2. Depression 3. Multiple chronic conditions
Provide patient population that should be included in the study
Case management for integrated care of older people with frailty in community settings
1. Aged 80 and over 80+ years 2. Frailty 3. Aged 65-79 years 4. Healthy
Provide patient population that should be included in the study
Medication review in hospitalised patients to reduce morbidity and mortality
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hospitalization 6. Aged 65-79 years
Provide patient population that should be included in the study
Comprehensive Geriatric Assessment for community‐dwelling, high‐risk, frail, older people
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Frail Elderly 4. Aged 65-79 years
Provide patient population that should be included in the study
Discharge planning from hospital
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Hospitalization 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Early warning systems and rapid response systems for the prevention of patient deterioration on acute adult hospital wards
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hospitalization 6. Aged 65-79 years
Provide patient population that should be included in the study
Routine provision of feedback from patient‐reported outcome measurements to healthcare providers and patients in clinical practice
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Decision‐support tools via mobile devices to improve quality of care in primary healthcare settings
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years
Provide patient population that should be included in the study
Telerehabilitation services for stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Stroke 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Subarachnoid Hemorrhage 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacy‐based management for depression in adults
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Depression
Provide patient population that should be included in the study
Manually‐generated reminders delivered on paper: effects on professional practice and patient outcomes
1. Healthcare Professional
Provide patient population that should be included in the study
Telephone counselling for smoking cessation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Smoker 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Stopped Smoking 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Follow‐up services for improving long‐term outcomes in intensive care unit (ICU) survivors
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Care Of Intensive Care Unit Patient 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Patient‐mediated interventions to improve professional practice
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Impact of public release of performance data on the behaviour of healthcare consumers and providers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Healthcare consumer 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Healthcare Provider 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacist services for non‐hospitalised patients
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Aged 65-79 years
Provide patient population that should be included in the study
Hospitalisation in short‐stay units for adults with internal medicine diseases and conditions
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Hospitalization 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Nurses as substitutes for doctors in primary care
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Physical complaint 8. Healthcare Professional 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Improving adherence to Standard Precautions for the control of health care‐associated infections
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare associated infectious disease 4. Healthcare Professional 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Comprehensive geriatric assessment for older people admitted to a surgical service
1. Aged 80 and over 80+ years 2. Preoperative State 3. Postoperative State 4. Aged 65-79 years
Provide patient population that should be included in the study
Patient reminder and recall interventions to improve immunization rates
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Adult 19-44 years 5. Immunization 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Providing physicians with feedback on medication adherence for people with chronic diseases taking long‐term medication
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Physician 5. Aged 65-79 years
Provide patient population that should be included in the study
Interventions to change the behaviour of health professionals and the organisation of care to promote weight reduction in children and adults with overweight or obesity
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Weight Control Education 4. Healthcare Professional 5. Young Adult 19-24 years
Provide patient population that should be included in the study
Comprehensive geriatric assessment for older adults admitted to hospital
1. Aged 80 and over 80+ years 2. Hospitalization 3. Aged 65-79 years
Provide patient population that should be included in the study
Interprofessional collaboration to improve professional practice and healthcare outcomes
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Healthcare Professional 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Home or foster home care versus institutional long‐term care for functionally dependent older people
1. Aged 80 and over 80+ years 2. Functionally dependent 3. Aged 65-79 years
Provide patient population that should be included in the study
Non‐medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Tools developed and disseminated by guideline producers to promote the uptake of their guidelines
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Young Adult 19-24 years 5. Health system manager 6. Policy maker
Provide patient population that should be included in the study
Mobile clinics for women's and children's health
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Integrated management of childhood illness (IMCI) strategy for children under five
1. Child, Preschool 2-5 years 2. Infant 1 to 23 mo 3. Illness 4. Birth to 1 mo
Provide patient population that should be included in the study
Professional interventions for general practitioners on the management of musculoskeletal conditions
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Transition of care for adolescents from paediatric services to adult health services
1. Chronic Disease 2. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions to optimise prescribing for older people in care homes
1. Aged 80 and over 80+ years 2. Institutionalized 3. Aged 65-79 years
Provide patient population that should be included in the study
Interactive telemedicine: effects on professional practice and health care outcomes
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Alternative versus standard packages of antenatal care for low‐risk pregnancy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Medical day hospital care for older people versus alternative forms of care
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Older Adult Care 4. Elderly 5. Aged 65-79 years
Provide patient population that should be included in the study
Chronic disease management programmes for adults with asthma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Asthma
Provide patient population that should be included in the study
In‐service training for health professionals to improve care of seriously ill newborns and children in low‐income countries
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Young Adult 19-24 years 5. Newborn Care Management 6. Paediatric Care
Provide patient population that should be included in the study
Case management approaches to home support for people with dementia
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Aged 65-79 years 4. Dementia
Provide patient population that should be included in the study
Dental auxiliaries for dental care traditionally provided by dentists
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. HIV infection 6. Aged 65-79 years
Provide patient population that should be included in the study
Computerized advice on drug dosage to improve prescribing practice
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Healthcare Professional 4. Young Adult 19-24 years 5. Patient care
Provide patient population that should be included in the study
Nutritional screening for improving professional practice for patient outcomes in hospital and primary care settings
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Primary healthcare services 5. Young Adult 19-24 years 6. Hospitalization 7. Aged 65-79 years
Provide patient population that should be included in the study
Managerial supervision to improve primary health care in low‐ and middle‐income countries
1. Healthcare Professional 2. Lay health worker support
Provide patient population that should be included in the study
Dressings and topical agents containing hyaluronic acid for chronic wound healing
1. Leg Ulcer 2. Foot Ulcer 3. Pressure ulcer
Provide patient population that should be included in the study
Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Diabetic Macular Edema 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Fenofibrate for diabetic retinopathy
1. Diabetes Mellitus
Provide patient population that should be included in the study
Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial disease or diabetes
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Amputated Below Knee 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Anti‐vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Proliferative Diabetic Retinopathy 5. Young Adult 19-24 years 6. Vitrectomy 7. Aged 65-79 years
Provide patient population that should be included in the study
Blood pressure control for diabetic retinopathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Type 2 Diabetes Mellitus 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Proliferative Diabetic Retinopathy 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Parathyroidectomy for adults with primary hyperparathyroidism
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Primary hyperparathyroidism 6. Aged 65-79 years
Provide patient population that should be included in the study
Antenatal dietary supplementation with myo‐inositol for preventing gestational diabetes
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacological interventions for prevention of weight gain in people with schizophrenia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Schizophrenic Related Disorders 6. Schizophrenia 7. Aged 65-79 years
Provide patient population that should be included in the study
Rituximab for thyroid‐associated ophthalmopathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Thyroid Eye Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre
1. Non-toxic Multinodular Goiter
Provide patient population that should be included in the study
Through‐knee versus above‐knee amputation for vascular and non‐vascular major lower limb amputations
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Lower limb amputation 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Continuous glucose monitoring systems for monitoring cystic fibrosis‐related diabetes
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Cystic fibrosis related diabetes
Provide patient population that should be included in the study
Nutritional supplementation for nonalcohol‐related fatty liver disease: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Non-alcoholic fatty liver disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Lifestyle modifications for nonalcohol‐related fatty liver disease: a network meta‐analysis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Non-alcoholic fatty liver disease 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for weight loss in people with chronic kidney disease who are overweight or obese
1. Adult 19-44 years 2. Obesity 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Chronic Kidney Disease 6. Overweight
Provide patient population that should be included in the study
Interventions for preventing type 2 diabetes in adults with mental disorders in low‐ and middle‐income countries
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Low Middle Income 4. Young Adult 19-24 years 5. Mental disorder
Provide patient population that should be included in the study
Psychological interventions for treating foot ulcers, and preventing their recurrence, in people with diabetes
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Diabetic Foot Ulcer 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Hormone Replacement Therapy 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Impaired Fasting Glucose
Provide patient population that should be included in the study
(Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Diabetes Mellitus 6. Aged 65-79 years
Provide patient population that should be included in the study
Minimally invasive parathyroidectomy guided by intraoperative parathyroid hormone monitoring (IOPTH) and preoperative imaging versus bilateral neck exploration for primary hyperparathyroidism in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Hyperparathyroidism
Provide patient population that should be included in the study
Nutritional interventions for treating foot ulcers in people with diabetes
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Foot Ulcer 5. Young Adult 19-24 years 6. Diabetes Mellitus 7. Aged 65-79 years
Provide patient population that should be included in the study
Metformin monotherapy for adults with type 2 diabetes mellitus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Type 2 Diabetes Mellitus 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Non‐nutritive sweeteners for diabetes mellitus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Diabetes Mellitus 6. Aged 65-79 years
Provide patient population that should be included in the study
Zinc supplementation for the promotion of growth and prevention of infections in infants less than six months of age
1. Infant 1 to 23 mo 2. Term infant (37-41 weeks) 3. Breast Fed
Provide patient population that should be included in the study
Resveratrol for adults with type 2 diabetes mellitus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Diabetes Mellitus 6. Aged 65-79 years
Provide patient population that should be included in the study
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Impaired Fasting Glucose
Provide patient population that should be included in the study
Oxandrolone for growth hormone‐treated girls aged up to 18 years with Turner syndrome
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Turner Syndrome 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Thyroxine replacement for subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Subfertility 4. Autoimmune thyroid disorder 5. In Vitro Fertilization 6. Young Adult 19-24 years 7. Euthyroid 8. Subclinical Hypothyroidism
Provide patient population that should be included in the study
Techniques of monitoring blood glucose during pregnancy for women with pre‐existing diabetes
1. Adult 19-44 years 2. Pre-existing Diabetes Mellitus In Pregnancy 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pregnancy 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Type 2 Diabetes Mellitus 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Transperitoneal versus retroperitoneal laparoscopic adrenalectomy for adrenal tumours in adults
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Adrenal Neoplasms 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Alpha‐glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Sliding scale insulin for non‐critically ill hospitalised adults with diabetes mellitus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Hospitalization 6. Diabetes Mellitus 7. Aged 65-79 years
Provide patient population that should be included in the study
Tocilizumab for thyroid eye disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Thyroid Eye Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Diabetic Foot 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Diabetic Foot Ulcer 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Monotherapy laser photocoagulation for diabetic macular oedema
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Diabetic Macular Edema 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes
1. Adult 19-44 years 2. Obesity 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pregnancy 6. Adolescent 13-18 years 7. Overweight
Provide patient population that should be included in the study
Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Diabetic Macular Edema 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Different lasers and techniques for proliferative diabetic retinopathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Proliferative Diabetic Retinopathy 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Planned birth at or near term for improving health outcomes for pregnant women with pre‐existing diabetes and their infants
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Type 2 Diabetes Mellitus 4. Young Adult 19-24 years 5. Term Pregnancy 6. Type 1 Diabetes Mellitus 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Hyperglycemia 4. Middle Aged 45-64 years 5. Impaired Glucose Tolerance 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Insulin for the treatment of women with gestational diabetes
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Gestational Diabetes Mellitus 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral anti‐diabetic agents for women with established diabetes/impaired glucose tolerance or previous gestational diabetes planning pregnancy, or pregnant women with pre‐existing diabetes
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Impaired Glucose Tolerance 4. Young Adult 19-24 years 5. Pregnancy 6. Impaired Glucose Tolerance Resolved 7. Diabetes Mellitus 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychological interventions for diabetes‐related distress in adults with type 2 diabetes mellitus
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Type 2 Diabetes Mellitus 5. Young Adult 19-24 years 6. Distress 7. Aged 65-79 years
Provide patient population that should be included in the study
Preconception care for diabetic women for improving maternal and infant health
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Diabetes Mellitus 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Phototherapy for treating foot ulcers in people with diabetes
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Type 2 Diabetes Mellitus 4. Young Adult 19-24 years 5. Diabetic Foot Ulcer 6. Type 1 Diabetes Mellitus
Provide patient population that should be included in the study
Topical antimicrobial agents for treating foot ulcers in people with diabetes
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Diabetic Foot Ulcer 10. Diabetes Mellitus 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Glucose targets for preventing diabetic kidney disease and its progression
1. Kidney disease 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Diabetes Mellitus
Provide patient population that should be included in the study
Dipeptidyl‐peptidase (DPP)‐4 inhibitors and glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Lifestyle interventions for the treatment of women with gestational diabetes
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Gestational Diabetes Mellitus 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Supportive interventions for enhancing dietary intake in malnourished or nutritionally at‐risk adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Malnutrition 6. Aged 65-79 years 7. Adolescent 13-18 years 8. At Risk For Nutritional Problem
Provide patient population that should be included in the study
Drug interventions for the treatment of obesity in children and adolescents
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Obesity 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Type 1 Diabetes Mellitus 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Fortification of staple foods with zinc for improving zinc status and other health outcomes in the general population
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes
1. Adult 19-44 years 2. Pre-existing Diabetes Mellitus In Pregnancy 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pregnancy 6. Gestational Diabetes Mellitus 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Autologous platelet‐rich plasma for treating chronic wounds
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Chronic Wound 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Different intensities of glycaemic control for pregnant women with pre‐existing diabetes
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Pre-existing Diabetes Mellitus 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Self management interventions for type 2 diabetes in adult people with severe mental illness
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Type 2 Diabetes Mellitus 5. Young Adult 19-24 years 6. Mental disorder 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Sodium‐glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Radioiodine therapy versus antithyroid medications for Graves' disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Graves' Disease 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Skin grafting and tissue replacement for treating foot ulcers in people with diabetes
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Type 2 Diabetes Mellitus 4. Young Adult 19-24 years 5. Diabetic Foot Ulcer 6. Type 1 Diabetes Mellitus 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Diabetic Ketoacidosis 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Diabetes Mellitus 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Intensive versus conventional glycaemic control for treating diabetic foot ulcers
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Type 2 Diabetes Mellitus 4. Young Adult 19-24 years 5. Diabetic Foot Ulcer 6. Type 1 Diabetes Mellitus
Provide patient population that should be included in the study
Parent‐only interventions for childhood overweight or obesity in children aged 5 to 11 years
1. Child, Preschool 2-5 years 2. Child 6-12 years 3. Obesity 4. Overweight
Provide patient population that should be included in the study
Thyroid surgery for Graves’ disease and Graves’ ophthalmopathy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Thyroid Eye Disease 10. Graves' Disease 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Growth factors for treating diabetic foot ulcers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Diabetic Foot Ulcer 6. Aged 65-79 years
Provide patient population that should be included in the study
Aromatase inhibitors for short stature in male children and adolescents
1. Child, Preschool 2-5 years 2. Short Stature 3. Child 6-12 years 4. Adolescent 13-18 years
Provide patient population that should be included in the study
Systemic antibiotics for treating diabetic foot infections
1. Aged 80 and over 80+ years 2. Infection 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Type 2 Diabetes Mellitus 6. Young Adult 19-24 years 7. Diabetic Foot Ulcer 8. Type 1 Diabetes Mellitus 9. Aged 65-79 years 10. Infection Of Foot Associated With Diabetes 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Complex interventions for preventing diabetic foot ulceration
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Type 2 Diabetes Mellitus 5. Young Adult 19-24 years 6. Type 1 Diabetes Mellitus 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Total or near‐total thyroidectomy versus subtotal thyroidectomy for multinodular non‐toxic goitre in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Non-toxic Multinodular Goiter 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Hyperbaric oxygen therapy for chronic wounds
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Chronic Wound 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical non‐steroidal anti‐inflammatory agents for diabetic cystoid macular oedema
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Diabetic Macular Edema 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Chronic Kidney Disease 5. Secondary hyperparathyroidism
Provide patient population that should be included in the study
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Type 1 Diabetes Mellitus 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Transtheoretical model stages of change for dietary and physical exercise modification in weight loss management for overweight and obese adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Obesity 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Overweight
Provide patient population that should be included in the study
Vitamin D supplementation for prevention of mortality in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Blue‐light filtering spectacle lenses for visual performance, sleep, and macular health in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Laser‐assisted cataract surgery versus standard ultrasound phacoemulsification cataract surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Cataract 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Antibiotics versus placebo for acute bacterial conjunctivitis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Bacterial Conjunctivitis 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Device‐modified trabeculectomy for glaucoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pigmentary Glaucoma 6. Angle-closure Glaucoma 7. Neovascular Glaucoma 8. Exfoliation glaucoma 9. Aged 65-79 years 10. Open-angle Glaucoma
Provide patient population that should be included in the study
Lens extraction versus laser peripheral iridotomy for acute primary angle closure
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Angle-closure Glaucoma 5. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for acute non‐arteritic central retinal artery occlusion
1. Central Retinal Artery Occlusion
Provide patient population that should be included in the study
Trifocal intraocular lenses versus bifocal intraocular lenses after cataract extraction among participants with presbyopia
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cataract Surgery 6. Aged 65-79 years
Provide patient population that should be included in the study
Iridotomy to slow progression of visual field loss in angle‐closure glaucoma
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Primary Angle-closure Glaucoma 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Birth to 1 mo 7. Aged 65-79 years
Provide patient population that should be included in the study
Early vitrectomy for exogenous endophthalmitis following surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Endophthalmitis 6. Aged 65-79 years
Provide patient population that should be included in the study
Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure
1. Endophthalmitis
Provide patient population that should be included in the study
Tocilizumab for giant cell arteritis
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Giant Cell Arteritis 4. Aged 65-79 years
Provide patient population that should be included in the study
Immediate sequential bilateral surgery versus delayed sequential bilateral surgery for cataracts
1. Aged 80 and over 80+ years 2. Bilateral Cataracts 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years